RE: More good press6 Aug 2020 14:26
Comparisons to the late 90s ‘tech boom’ do not seem to be that far from reality, with biotech groups, particularly among small caps, seeing their share prices surge over the last six months as investors scrabble to ride the wave of efforts to treat and possibly cure the coronavirus.
One such beneficiary is Synairgen PLC (LON:SNG), which has seen its share price rocket into the stratosphere since that start of 2020, rising over 3,300% since early January.
READ: Synairgen boss says SNG001 results “a clearer signal than we could have dared hope for”
The company recently reported positive results from a clinical trial of its drug SNG001, an inhaled formulation of interferon beta designed to help treat symptoms of coronavirus.
The firm has also looked to take advantage of its recent surge, raising £14mln in late March to fund the trial of its interferon-beta treatment.